



FOXL2 is a Progesterone Target Gene in the Endometrium of Ruminants

Caroline Eozenou, Audrey Lesage-Padilla, Vincent Mauffré, Gareth Healey, Sylvaine Camous, Philippe Bolifraud, Corinne Giraud-Delville, Daniel Vaiman, Takashi Shimizu, Akio Miyamoto, et al.

► To cite this version:

Caroline Eozenou, Audrey Lesage-Padilla, Vincent Mauffré, Gareth Healey, Sylvaine Camous, et al.. FOXL2 is a Progesterone Target Gene in the Endometrium of Ruminants. International Journal of Molecular Sciences, 2020, 21 (4), pp.1478. 10.3390/ijms21041478 . hal-02891695

HAL Id: hal-02891695

<https://hal.science/hal-02891695>

Submitted on 15 Oct 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Article

FOXL2 is a Progesterone Target Gene in the Endometrium of Ruminants

Caroline Eozenou ^{1,2,*}, Audrey Lesage-Padilla ¹, Vincent Mauffré ¹ , Gareth D. Healey ³ ,
Sylvaine Camous ¹, Philippe Bolifraud ¹, Corinne Giraud-Delville ¹, Daniel Vaiman ⁴ ,
Takashi Shimizu ⁵, Akio Miyamoto ⁵ , Iain Martin Sheldon ³ , Fabienne Constant ¹,
Maëlle Pannetier ¹ and Olivier Sandra ^{1,*}

¹ Université Paris-Saclay, INRAE, ENVA, UVSQ, BREED, 78350 Jouy-en-Josas, France; audrey.lesage.padilla@gmail.com (A.L.-P.); vincent.mauffre@vet-alfort.fr (V.M.); sylvaine.camous@gmail.com (S.C.); philippe.bolifraud@orange.fr (P.B.); Corinne.Giraud-Delville@inrae.fr (C.G.-D.); fabienne.constant@vet-alfort.fr (F.C.); maelle.pannetier@inrae.fr (M.P.)

² Institut Pasteur, UMR 3738, Biologie du Développement et Cellules Souches, Laboratoire de Génétique du Développement Humain, 25 rue du docteur roux, F75015 Paris, France

³ Swansea University Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK; g.d.healey@swansea.ac.uk (G.D.H.); i.m.sheldon@swansea.ac.uk (I.M.S.)

⁴ Institut Cochin, INSERM U1016, UMR 8104 CNRS, Faculté René Descartes, 24 rue du Faubourg St Jacques, 75014 Paris, France; daniel.vaiman@inserm.fr

⁵ Obihiro University of Agriculture and Veterinary Medicine, Obihiro 080-8555, Japan; shimizut@obihiro.ac.jp (T.S.); akiomiya@obihiro.ac.jp (A.M.)

* Correspondence: caroline.eozenou@pasteur.fr (C.E.); olivier.sandra@inrae.fr (O.S.); Tel.: +33-144389136 (C.E.); +33-134642343 (O.S.)

Received: 7 January 2020; Accepted: 19 February 2020; Published: 21 February 2020



Abstract: Forkhead Box L2 (FOXL2) is a member of the FOXL class of transcription factors, which are essential for ovarian differentiation and function. In the endometrium, FOXL2 is also thought to be important in cattle; however, it is not clear how its expression is regulated. The maternal recognition of pregnancy signal in cattle, interferon-Tau, does not regulate FOXL2 expression. Therefore, in the present study, we examined whether the ovarian steroid hormones that orchestrate implantation regulate FOXL2 gene expression in ruminants. In sheep, we confirmed that FOXL2 mRNA and protein was expressed in the endometrium across the oestrous cycle (day 4 to day 15 post-oestrus). Similar to the bovine endometrium, ovine FOXL2 endometrial expression was low during the luteal phase of the oestrous cycle (4 to 12 days post-oestrus) and at implantation (15 days post-oestrus) while mRNA and protein expression significantly increased during the luteolytic phase (day 15 post-oestrus in cycle). In pregnant ewes, inhibition of progesterone production by trilostane during the day 5 to 16 period prevented the rise in progesterone concentrations and led to a significant increase of FOXL2 expression in caruncles compared with the control group (1.4-fold, $p < 0.05$). Ovariectomized ewes or cows that were supplemented with exogenous progesterone for 12 days or 6 days, respectively, had lower endometrial FOXL2 expression compared with control ovariectomized females (sheep, mRNA, 1.8-fold; protein, 2.4-fold; cattle; mRNA, 2.2-fold; $p < 0.05$). Exogenous oestradiol treatments for 12 days in sheep or 2 days in cattle did not affect FOXL2 endometrial expression compared with control ovariectomized females, except at the protein level in both endometrial areas in the sheep. Moreover, treating bovine endometrial explants with exogenous progesterone for 48h reduced FOXL2 expression. Using in vitro assays with COS7 cells we also demonstrated that progesterone regulates the FOXL2 promoter activity through the progesterone receptor. Collectively, our findings imply that endometrial FOXL2 is, as a direct target of progesterone, involved in early pregnancy and implantation.

Keywords: FOXL2; endometrium; sheep; cattle; progesterone

1. Introduction

In mammals, successful implantation and pregnancy depends on a tightly regulated cross-talk between the ovary, the endometrium and the conceptus (embryonic disk and extra-embryonic tissues), which takes place during the peri-implantation period [1–4]. In cattle, conceptus elongates during the first three weeks of pregnancy, ending with implantation on day 19 to 20 post-oestrus [5,6]. During implantation, environmental factors including infections, stress, nutrition or endocrine disruptors can alter this cross-talk leading to early embryonic death [7,8]. In cattle and more specifically in dairy cows, up to two thirds of pregnancies are lost as a consequence of early embryonic death [9,10]. Deciphering the molecular mechanisms of implantation is essential to understand how implantation supports fetoplacental development and affects pregnancy outcome [1,3].

Endometrial receptivity and embryo implantation occur during the luteal phase of the oestrous cycle. The receptive status of the endometrium requires combined actions by the ovarian steroid hormones, oestrogen (E2) and progesterone (P4) [11–17]. Oestrogen is secreted during 4 to 5 days of the follicular phase in cattle [18,19], which is shorter than the 14-day follicular phase in humans (14 days, [18,20–22]). In ruminants, the short-term secretion of E2 is not associated with endometrial growth [18], whereas E2 and P4 regulate the proliferation of endometrial cells during the follicular phase in humans, as a prerequisite for invasive implantation [5,22,23]. Progesterone controls the differentiation and secretions of endometrial glands (histotroph; [15,23]) as well as endometrial angiogenesis [15,24]. These processes are essential for ensuring endometrial receptivity, a prerequisite for the establishment and the maintenance of pregnancy as well as conceptus elongation [25–27]. The elongating conceptus produces interferon-tau (IFNT), as the major signal of the maternal recognition of pregnancy in ruminants [28–30]. Secretion of IFNT prevents regression of the corpus luteum, leading to continued secretion of P4 [31,32]. Despite the importance of P4, the molecular and cellular mechanisms regulated by this hormone are still the object of intense investigation [33,34]. The biological actions of E2 and P4 are mainly mediated by their nuclear receptors, Estrogen Receptor (ESR1-2, formerly named ER α - β , transcribed from two distinct genes) and Progesterone nuclear Receptor (PGR α -B, two isoforms from the same gene; [15,35]), respectively. Upon binding with E2 or P4, the receptors translocate to the nucleus and modulate expression of E2 or P4 target genes [15,35–38]. In the last decade, studies have identified direct target genes of ESR and PGR in humans, rodents and cattle [39]. These genes are involved in the repression of the E2 signalling pathway (*NR2F2/COUP-TFII*; [38]), proliferation of endometrial cells (i.e., *IGF1* and *EGR1*; [35,38]), uterine receptivity (*FOXO1*, [40]) and decidualisation (*NR2F2/COUP-TFII*, *WNT4*, *HOXA10*; [38]). This non-exhaustive list of steroids targeting genes in the endometrium includes transcription factors that represent regulation nodes of endometrial receptivity and physiology. The biological actions of E2 and P4 are essential for pregnancy outcome but their orchestration is not yet fully elucidated.

In ruminants, transcriptomics has provided a genome-wide understanding of factors involved in endometrial physiology during the oestrous cycle and implantation [25,41–50]. At the time of implantation, transcriptional regulation of transcription factor expression was reported for several members of the winged-helix/forkhead domain (FOX) transcription factors family in the bovine endometrium [44], including Forkhead Box L2 (*FOXL2*), which appears to be important in the endometrium as well as a key gene involved in ovarian differentiation and maintenance of ovarian function from foetal life to adulthood [51–53]. Since our first identification of *FOXL2* in the endometrium [52], this transcription factor has been reported to be expressed in endometriotic lesions in humans [54], involved in uterus maturation [55] as well as endometrial cell adhesion with the trophoblast in mice [56]. However, regulation of *FOXL2* gene expression was IFNT-independent [52] and there was a negative correlation between circulating P4 concentrations and *FOXL2* gene expression in the bovine endometrium [52]. Therefore, the present study aimed to determine if *FOXL2* is a P4

target gene in the endometrium of ruminants. The relationship between P4 and *FOXL2* expression was explored using multiple approaches combining physiological situations in cattle and sheep, in vivo experimental models, as well as in vitro models including *FOXL2* promoter analysis in COS cells.

2. Results

2.1. *FOXL2* is Expressed in the Ovine Endometrium

In sheep, the oestrous cycle lasts 15 to 17 days, and is associated with an increase in P4 secretion (day 5 to 6), which reaches a plateau before decreasing (day 14 to 15) in parallel with corpus luteum regression [25].

In sheep, *FOXL2* mRNA and protein were expressed in the caruncular (CAR) and intercaruncular (ICAR) endometrium, and the expression was regulated during the oestrous cycle and implantation (Figure 1). In Western blot analysis, *FOXL2* protein was detectable at 50 kDa, as reported previously in cattle [52]. Expression profiles of *FOXL2* were similar for mRNA and protein (Figure 1A,B). Endometrial *FOXL2* expression was significantly higher in CAR areas than in ICAR areas (Figure 1A,B, 3-fold for the mRNA and 5-fold for the protein; $p < 0.001$). During the oestrous cycle, *FOXL2* mRNA and protein expression was higher in early luteal phase (day 4, 1.5-fold) and follicular phase (day 15, 2-fold), compared with the mid-luteal (day 8) and active luteal phase (day 12), as well as at implantation (day 15), especially in CAR areas ($p < 0.05$).




Figure 1. *FOXL2* expression in ovine endometrium. Caruncular (CAR) and intercaruncular (ICAR) endometrial areas were collected from cyclic Pré-alpes du sud ewes at various days post-oestrus (day 4, $n = 4$; day 8, $n = 4$; day 12, $n = 4$). Two experimental groups were subsequently added to this study, then CAR and ICAR endometrial areas were collected from cyclic ($n = 4$) and pregnant ($n = 4$) Pré-alpes du sud ewes at 15 days post-oestrus. (A) Quantification of *FOXL2* mRNA by RT-qPCR. Expression of *FOXL2* gene was normalised against that of *RPL19*. (B) Quantification of *FOXL2* protein by Western blotting. The amount of *FOXL2* was normalized to that of *ACTB*. Quantitative data are presented as the mean $\pm$ SEM. * $p < 0.05$.

2.2. Endometrial FOXL2 Gene Expression Varies with Blood P4 Concentrations in Sheep

Since endometrial *FOXL2* gene expression decreased when circulating P4 concentrations increased, two ovine experimental models were generated to further analyse the impact of P4 on *FOXL2* endometrial expression.

Two groups of pregnant ewes were treated with either DMSO solution (control group) or a solution of trilostane, an inhibitor of 3β -HSD, which catalyses the conversion of pregnenolone into progesterone. Trilostane treatment was applied from day 6 to 16 of pregnancy, preventing the P4 concentration increase during the early luteal phase, with a steady concentration of circulating P4 during early pregnancy (Figure 2A). Compared with the control group, *FOXL2* mRNA expression was higher in the CAR endometrium at 16 days of pregnancy in the trilostane-treated group (Figure 2B; 1.4-fold, $p < 0.05$). At the protein level, a trend toward an increase in *FOXL2* expression was observed in the CAR areas of the trilostane-treated ewes (Figure 2C, $p = 0.14$).

In order to mimic the ovarian oestrous cycle, ovariectomized ewes were supplemented for 12 days with control solution (control group) or ovarian steroid solutions (P4, E2 or a combination of both) [57]. A group of cyclic ewes at 12 days post-oestrus was included in the experimental design in order to determine the effect of ovariectomy on endometrial gene expression. *FOXL2* mRNA and protein were detected in every experimental condition, and both displayed a significant higher expression in the CAR areas compared with the ICAR areas of the endometrium (Figure 3; mRNA and protein, average of 2-fold for mRNA and 3-fold for protein, $p < 0.05$). A significant increase in *FOXL2* transcript expression was observed in the endometrium of the ovariectomized ewes (OVX) compared with the cyclic group (2-fold, $p < 0.05$). Compared with the OVX group, oestradiol (E2) supplementation did not significantly alter *FOXL2* mRNA expression (Figure 3A), whereas *FOXL2* protein levels were increased in the ICAR area (Figure 3B; 2.5-fold, $p < 0.05$). Progesterone (P4) supplementation significantly reduced the expression of *FOXL2* mRNA (CAR and ICAR area; 2-fold, $p < 0.05$) and protein (CAR only; 2.5-fold, $p < 0.05$) compared with the control group. In the OVX group supplemented with P4 and E2, *FOXL2* mRNA expression did not significantly differ from *FOXL2* mRNA expression in the OVX, (E2), (P4) and cyclic groups.




Figure 2. Cont.




Figure 2. Regulation of *FOXL2* gene expression in ewes with lower circulating P4 concentrations. Caruncular (CAR) and intercaruncular (ICAR) endometrial areas were collected from pregnant Pré-alpes du sud ewes treated with DMSO as a control solution ($n = 7$) or with trilostane (15 mg/ewe in 1 mL DMSO; twice a day, $n = 10$) for 11 days. (A) Progesterone dosage throughout the treatment: DMSO ($n = 7$) or Trilostane ($n = 10$) for 11 days. (B) Quantification of *FOXL2* mRNA by RT-qPCR. Expression of *FOXL2* was normalized to that of *RPL19*. (C) Quantification of *FOXL2* protein by Western blotting. The amount of *FOXL2* was normalized to that of *ACTB*. Quantitative data are presented as mean $\pm$ SEM. * $p < 0.05$.




Figure 3. *FOXL2* endometrial expression in ovariectomized ewes supplemented with ovarian steroids. Caruncular (CAR) and intercaruncular (ICAR) endometrial areas were collected from ovariectomized Pré-alpes du sud ewes supplemented with a control solution (OVX, $n = 4$), (P4) solution (OVX + P4, $n = 4$), (E2) solution (OVX + E2, $n = 4$) or (P4 + E2) solution (OVX + E2 + P4, $n = 4$) for 12 days and also from cyclic ewes at 12 days ($n = 4$). (A) Quantification of *FOXL2* mRNA by RT-qPCR. Expression of *FOXL2* was normalized to that of *RPL19*. (B) Quantification of *FOXL2* protein by Western blotting. The amount of *FOXL2* was normalized to that of *ACTB*. Quantitative data are presented as mean $\pm$ SEM. * $p < 0.05$.

2.3. P4 Supplementation Reduces Endometrial FOXL2 Gene Expression in Cattle

Ovariectomized cows were supplemented with E2, P4 or both steroids as described previously [58]. Similar to the ovine OVX model, a significant reduction in endometrial *FOXL2* mRNA expression was detected in (P4)- and (P4 + E2)-supplemented cows, compared with the OVX group (Figure 4A, 2.03-fold and 2-fold respectively, $p < 0.05$). Supplementation with E2 had no significant effect on endometrial *FOXL2* mRNA expression compared with OVX cows.

Using bovine endometrial explants treated with E2 or P4 for 48h, a significant decrease in *FOXL2* mRNA expression was observed in the P4 treatment group, compared with control or E2 treatment (Figure 4B upper panel, 2.7-fold and 2.3-fold respectively, $p < 0.05$). The expression of *PGR* was also reduced, compared with control or E2 treatment (Figure 4B lower panel, control versus P4 supplementation, 2-fold; P4 versus E2 supplementation, 3.5-fold, $p < 0.05$).




Figure 4. *FOXL2* endometrial expression under the influence of ovarian steroid hormones balance in ovariectomized cows and bovine explants. The expression of *FOXL2* was quantified by RT-qPCR, and normalized to *RPL19*. **(A)** Strips of endometrial tissue were collected from ovariectomized cows supplemented with a control solution (OVX; $n = 3$), progesterone (OVX + P4; $n = 3$), oestradiol (OVX + E2; $n = 3$) or both steroids (OVX + E2 + P4; $n = 3$). Data were analysed by ANOVA and are presented as the mean $\pm$ SEM. Bars with different superscripts significantly differ ($p < 0.05$). **(B)** Intercaruncular endometrial explants from two cows were cultured ex vivo for 48 h in control medium (C), or medium containing 5 ng/mL progesterone (P4) or 3 pg/mL oestradiol (E2). The expression of *FOXL2* and *PGR* transcripts was quantified by RT-qPCR and normalized to *RPL19* gene expression. Data were analysed by ANOVA and are presented as the mean $\pm$ SEM. * $p < 0.05$.

2.4. P4 Directly Regulates the Activity of FOXL2 Promoter through Its Nuclear Receptor

Using transiently transfected COS-7 cells, *FOXL2* promoter activity was increased by P4 treatment when PGR-A, PGR-B or a combination of both PGR were overexpressed. (Figure 5, $p < 0.01$; $p < 0.001$). Overexpression of either PGR in the absence of P4 did not significantly modify the *FOXL2* promoter activity.




Figure 5. Progesterone regulates *FOXL2* promoter activity in vitro. COS7 cells were cultivated for few passages then transfected using Xtreme gene transfection reagent with progesterone receptor (PGR) A and/or B expressing vectors as well as *FOXL2*-promoter sequence (1 kb) associated with the luciferase gene for 48 h in the presence or absence of a progesterone (P4) treatment. Activity of the *FOXL2* promoter was normalized to TK-Renilla vector activity. Quantitative data are presented as the mean $\pm$ SEM. ** $p < 0.01$; *** $p < 0.001$.

3. Discussion

Since the *FOXL2* gene was cloned in 2001, it has been recognized as a key factor in ovarian differentiation and maintenance of ovarian function from foetal life to adulthood in vertebrates [51,53,59–62]. However, *FOXL2* is also expressed in the bovine endometrium and its expression was regulated throughout the oestrous cycle and early pregnancy [52]. Endometrial expression of *FOXL2* has been confirmed in several mammals, including mice [55,56], humans [54] and camels [63]. Surprisingly, IFNT, the signal for maternal recognition of pregnancy in ruminants, was not involved in *FOXL2* gene regulation [52]. Therefore, we explored whether ovarian steroids might regulate *FOXL2* expression. In the present study, we demonstrated that P4 regulates *FOXL2* expression in the endometrium of ruminants and stimulates *FOXL2* promoter activity through PGR nuclear receptors.

In mammals, P4 is essential for initiating and maintaining pregnancy [64]. The present study showed that experimental manipulation of circulating P4 concentrations were associated with variations in endometrial *FOXL2* gene expression in vivo. Ovariectomized ewes or cows supplemented with exogenous P4 had reduced endometrial *FOXL2* expression. This situation was recapitulated in vitro when endometrial explants were incubated with P4. Conversely, *FOXL2* gene expression was up-regulated when the circulating P4 concentrations were low. P4 primarily acts through the nuclear progesterone receptor (PGR), which is involved in uterine receptivity and embryo implantation [15,65,66]. The biological actions of PGR result from regulation of target genes expression when PGR binds to canonical or non-canonical Progesterone Response Element (PRE) motifs present in

proximal or distal regions of promoter sequences, modulated by the interactions with co-factors, such as other transcriptional regulators (e.g., ESR1, FOXA1, NCOA3, NCOA1, SRC—String analysis, [67]). In silico analysis of caprine, ovine and bovine *FOXL2* promoter sequences confirmed the presence of a PRE motif that suggests regulation of *FOXL2* gene expression by P4 [68,69]. The association of P4 with PGR affects the expression of numerous transcription factors, including FOXO1, HOXA10 or HAND2 [38], which are involved in cell differentiation and secretory protein production in the uterus [70]. The interaction between P4 and *FOXL2* expression was further evidenced using a COS7 cell line overexpressing PGR protein where P4 supplementation activated the *FOXL2* promoter. Therefore, based on the literature and our data, we hypothesize that *FOXL2* expression is regulated by ovarian steroids E2 and P4 in female reproductive tissues. Further investigations will be necessary to detail mechanisms that drive steroid regulation of *FOXL2* gene expression.

Our initial report [52] and present results demonstrate an inverse correlation between blood P4 concentrations and *FOXL2* gene expression in the endometrium of ruminants. In bovine endometrium, nuclear expression of PGR has been detected in stromal, luminal and glandular epithelia, and the sub-cellular localization of PGR has been shown to vary throughout the oestrous cycle [37]. The nuclear staining was detected during the follicular or early luteal phase when the circulating P4 concentrations were still low (5 days post-oestrus). The nuclear signal reduced with the progression of the luteal phase, and became undetectable in luminal and glandular epithelia during the active luteal phase when the P4 concentration was the highest (16 days post-oestrus; [37]). Similarly, bovine *FOXL2* protein was detectable in the nuclei of endometrial stroma and glandular epithelium during the follicular phase (20 days post-oestrus), with the signal intensity decreased in glandular epithelium during the luteal phase (14 days post-oestrus; [52]). Our results are consistent with data that reported *FOXL2* as the top gene in a list of 28 transcription factors identified as direct P4-target genes in human umbilical vein endothelial cells (HUVECs) infected with a PGR coding lentivirus [71]. In addition, expression patterns of *PGR* and *FOXL2* transcripts were similar in our model of ovariectomized cows, as well as during oestrous cycle and early pregnancy (published for *FOXL2* [52] and Figure S1 for *PGR*). During the oestrous cycle, it is well established that expression of nuclear PGR is downregulated in stromal and glandular cells of bovine endometrium when P4 rises [36,37]. The combination of the present study with former reports in humans [72,73] and cattle [52] indicates that the inverse correlation between P4 plasma levels and endometrial *FOXL2* gene expression does not reflect a negative action of P4 on *FOXL2* gene expression but results from the reduction of PGR expression in endometrial cells.

Steroid hormones act as critical trophic factors for normal development of numerous biological systems [74]. Oestradiol plays essential roles in female sex determination in non-mammalian vertebrates regardless of the sex determining mechanism [75] and in maintenance of ovarian function in mammalian species [76]. In mice, the combined effect of *FOXL2* and *ESR2* on granulosa cell identity was demonstrated by genome wide studies that showed common targets shared by *FOXL2* and *ESR2* [77]. On the other hand, *FOXL2* is also known to activate *ESR2* expression [77]. Furthermore, *FOXL2* stimulates ovarian *CYP19* gene expression, leading to increased E2 production in goats [78], chicken [79], in rainbow trout [80] and medaka fish [81]. These data suggest the existence of a coherent feed-forward loop in which *FOXL2* stimulates both oestradiol production and receptivity (i.e., *ESR2* expression). In our study, while *FOXL2* transcriptional levels were normal, *FOXL2* protein levels were increased by E2 treatment. This finding suggests a stabilization of the protein by post-translational modifications, such as SUMOylation [82] and/or direct interaction with *ESR* [61]. To our knowledge, this is the first report suggesting a role of oestrogens on *FOXL2* protein stabilization, through a feed-back loop. Further analysis will be necessary to elucidate the complex relationship between E2 and *FOXL2* protein expression in the endometrium.

Uterine receptivity is characterized by the intensive proliferation of endometrial cells mediated by E2 during the follicular phase and endometrial gland maturation, changes in endometrial genes expression and P4-mediated decidualisation during the luteal phase in rodents and human [12–17,83,84]. In ruminants including cattle, the oestrous cycle is characterized by a short follicular phase and

a long luteal phase [18] that are associated with increased and decreased *FOXL2* gene expression, respectively [52]. During the human menstrual cycle, *FOXL2* transcript expression was higher during the follicular phase in keeping with the regulation we reported in ruminants [73]. Altogether, our present and past data as well as other reports have shown that the *FOXL2* gene is expressed during the follicular phase of various mammalian species, suggesting that this transcription factor could be a key regulator of the proliferative process required for establishing uterine receptivity. In granulosa cells, *FOXL2* is involved in the pro-apoptotic process regulating the expression of *BCL2A1* and *ATF3* genes but also the anti-apoptotic process regulating the expression of *TNFAIP3*, *NR5A2* and *FOS* genes [85,86]. Further analyses will be necessary to clarify if *FOXL2* regulates pro- and anti-apoptotic balance as well as cell proliferation in the endometrium during reproductive cycles in mammals.

Since its identification, *FOXL2* gene has been considered as the gatekeeper of ovarian identity due to its highly conserved protein sequence in non-vertebrate and vertebrate species [87]. In mammalian species, new reproductive tissues appeared, including the uterus, placenta and mammary gland. Collectively, our data as well as GEO profiles, NextProt-Beta data and the human protein atlas have documented the expression of *FOXL2* in every female reproductive tissue: the oviduct, uterus (endometrium and myometrium), mammary gland and placenta [52,54–56,63,73,88]. Interestingly, whereas *FOXL2* is expressed in each reproductive tissue of mammalian female, its regulation varies with the nature of the reproductive tissue. Our current data have demonstrated that *FOXL2* is a progesterone-target gene in the endometrium. In mammalian species, identifying the molecular processes that drive tissue-specific regulation of *FOXL2* gene expression will be mandatory to understand the contribution of this transcription factor to the reproductive process.

4. Materials and Methods

4.1. Animal Experiments and Cell Cultures

All experimental procedures were completed in accordance with European Community Directive 86/609/EEC and 2010/63/EU and approved by the French Ministry of Agriculture according to French regulations for animal experimentation (authorization number 78-113, approval date 25 September 2006).

Experiment 1. *FOXL2* expression during the oestrous cycle and implantation in the ovine endometrium.

Cyclic and pregnant ewes of the Préalpes-du-Sud breed were synchronized using intravaginal pessaries [89]. Twelve ewes were randomly allocated to three groups ($n = 4$ ewes per group) corresponding to day 4, day 8 and day 12 of the oestrous cycle (representing the early, mid and active luteal phase, respectively). Eight additional ewes were randomly allocated to two groups ($n = 4$ ewes per group) corresponding to day 15 of the oestrous cycle (late luteal phase/follicular phase) and day 15 of pregnancy (implantation). Uteri were collected, flushed, and the stage of pregnancy was confirmed by the presence and morphology of the conceptus in uterine flushings [90]. Endometrial caruncular (CAR) and intercaruncular (ICAR) areas were dissected from the uterine horns ipsilateral to the corpus luteum, as described previously [89]. Endometrial samples were immediately snap frozen in liquid nitrogen, and stored at -80°C prior to analyses.

Experiment 2. Effect of reduced progesterone concentration on *FOXL2* expression in the ovine endometrium.

We investigated the impact of altered circulating P4 concentrations on *FOXL2* expression in ovine endometrium. Pregnant ewes were treated daily for 11 days with trilostane, an inhibitor of 3β -hydroxysteroid-deshydrogenase (3β -HSD) activity, which prevents the conversion of pregnenolone into P4. This ovine experimental model showed that the lower concentration of P4 did not affect conceptus morphology nor pregnancy rates at 16 days post-oestrus, but led to changes in endometrial gene expression.

Seventeen pregnant ewes were synchronised, as in Experiment 1. From day 6 to day 16 post-oestrus, the pregnant females received either subcutaneous injections of DMSO ($n = 7$) or Trilostane ($n = 10$). Trilostane (15 mg/ewe in 1 mL DMSO) or DMSO was injected every 12 h (08:00 AM and 08:00 PM) into the ewes [91]. Endometrial CAR and ICAR areas were collected and stored as described in Experiment 1.

Experiment 3. Effect of steroid hormone supplementation on *FOXL2* expression in the endometrium.

4.2. In Vivo Supplementation of Steroids in Ewes

Sixteen ewes of the Préalpes-du-Sud breed were ovariectomized (OVX). Then, 42 days after the ovariectomy, they were randomly allocated to five groups ($n = 4$ ewes per group): control ewes (OVX), E2-treated (OVX + E2), P4-treated (OVX + P4) and E2/P4-treated (OVX + E2 + P4) ewes, as described previously [11]. All steroid hormone treatments were administered in 1 mL of 90% corn oil/10% ethyl alcohol, at intervals of 8 h by intramuscular injection [11]. This steroid hormone administration protocol produces physiological blood concentrations of E2 and P4 [92], corresponding to those during the follicular and luteal phases in cyclic ewes [93]. A control group of 4 cyclic ewes at 12 days of the oestrus cycle was included in the experiment. Blood for monitoring the steroid hormone concentrations and endometrial tissue (CAR and ICAR areas) were collected and treated as described in Experiment 1.

4.3. In Vivo Supplementation of Steroids in Cows

Twelve Holstein cows (3 to 7 year of age) were ovariectomized (OVX). Fifty days after the ovariectomy, they were randomly divided into four groups ($n = 3$ cows per group): control cows, OVX (received saline treatment at day 0), OVX + E2 group (received 1 mg of estradiol benzoate (EB) at day 5), OVX + P4 group (the plasma concentration of P4 was increased to the levels of typical mid-luteal using two controlled internal drug release devices (CIDRs) (Pfizer, Tokyo, Japan) inserted into the vagina of animals from day 0 to day 6) and OVX + E2 + P4 group (received two CIDRs at day 0 and 1 mg of EB immediately after removal of the CIDRs at day 6) [58]. Endometrial tissue (ICAR areas) were collected, snap frozen and stored at -80°C .

4.4. Incubation of Bovine Endometrial Explants with Steroids

Endometrial explants were dissected from ICAR areas of the uterus of two cows in the late oestrus stage slaughtered at a commercial slaughterhouse, as part of the routine operation of the slaughterhouse [94]. The external surfaces of the uteri were washed in 70% ethanol. The exposed endometrium was washed in Dulbecco's phosphate-buffered saline solution (D-PBS; Sigma-Aldrich Ltd., Dorset, UK) supplemented with 50 IU/mL penicillin, 50 lg/mL streptomycin (Sigma-Aldrich, Saint-Louis, MO, USA) and 2.5 lg/mL amphotericin B (Sigma-Aldrich). Tissue was collected from the ICAR area of the endometrium using sterile 8-mm-diameter biopsy punches (Stiefel Laboratories Ltd., High Wycombe, UK). The explants were cultured ex vivo in 24-well plates (TPP, Trasadingen, Switzerland) containing 2 mL culture medium/well, comprising phenol red-free RPMI 1640 medium (Sigma-Aldrich) containing 10% heat inactivated, double charcoal-stripped, foetal bovine serum (Biosera, East Sussex, UK), as described previously [94,95]. In a former report [94], collection, processing and treatment of explants are described and illustrated with pictures, along with histology using Hematoxylin/Eosin and TUNEL staining to validate the methodology. Within 4 h of slaughter, the explants were treated with control medium, or medium containing E2 (3 pg/mL) or P4 (5 ng/mL) for 48 h. At the end of the culture period, the explants were collected and stored at -80°C in Trizol reagent (Invitrogen, Cergy-Pontoise, France) prior to RNA extraction.

4.5. Cell Culture Conditions and Transfections Assays in COS Cells

COS7 cells (Public Health England, Salisbury, UK) were cultured in phenol-red free Dulbecco's modified Eagle's media (DMEM)-F12 (Sigma, Saint-Louis, USA) supplemented with 10% (*v/v*)

heat-inactivated foetal calf serum, 2.52 mM L-glutamine (PAN-Biotech, Aidenbach, Germany), 430–16.4–15.8 nM Insulin-Transferin-Selenium (ITS, Sigma, Saint-Louis, USA), 100 UI/mL–340 nM Penicillin-Streptomycin (PAN-Biotech, Aidenbach, Germany), 100 UI/mL Nystatin (Sigma, Saint-Louis, USA), 2.7 µM Amphotericin B (PAN-Biotech, Aidenbach, Germany) and 104.7 µM Gentamicyn (Sigma, Saint-Louis, USA). Cells were maintained in 37 °C humidified incubator at 5% CO₂.

Cells were plated at a density of 100,000 cells/well in 24-well plates, and were allowed to grow until 90% confluent. After 24 h of steroid deprivation, cells were transfected using 500 ng caprine sequence of the *FOXL2* promoter cloned in pGL3b vector (1 kb proximal promoter, [78,96]), 250 ng pSG5, 250 ng PGRA, 250 ng PGRB or 250 ng PGRA + PGRB (125 ng each), and 10 ng TK-Renillia (internal control for normalisation, Promega Madison, USA) using 1 µL/well XtremeGENE HP DNA Transfection Reagent (Roche Applied Science, Mannheim, Germany). Progesterone Receptor (PGR)-A and -B expressing plasmids, cloned in pSG5 plasmid, were kindly provided by P. Chambon (INSERM, Institut de Chimie Biologique, Faculté de Médecine de Strasbourg, France; [97]). After the 24 h transfection, media were replaced with fresh complete media with 0.03% ethanol (vehicle) or 100 nM progesterone for another 24 h. Luciferase assays were performed with the Promega Dual-Luciferase Reporter Assay System, following the manufacturer's protocol using the injector Tristar LB941 (Berthold Technologies, Bad Wildbad, Germany), as described previously [78,96]. Each combination of plasmids was tested in duplicate, in three independent experiments.

4.6. Tissue and Cell Collection and RNA Extraction

Total RNA from frozen endometrial tissue and explants was isolated by homogenization using Trizol Reagent (Invitrogen, Cergy-Pontoise, France) as per the manufacturer's recommendations and purified using Qiagen columns integrating a DNase step (RNeasy mini-kit; Qiagen).

4.7. Real-Time RT-PCR

Total RNA samples were used for real-time RT-qPCR. A total of 1 µg of total RNA were reverse transcribed into cDNA as described previously [52]. Primers (Eurogentec, Liège, Belgium) were designed (Primer Express Software v2.0, Applied Biosystems) to amplify bovine and ovine *FOXL2* (F: CCGGCATCTACCAGTACATTATAGC; R: GCACTCGTTGAGGCTGAGGT; NCBI sequence reference: NM_001031750.1) and *RPL19* (F: CCCC AATGAGACCAATGAAATC; R: CAGCCCATCTTTGATCAGCTT). Amplified *FOXL2* and *RPL19* PCR fragments were sequenced to assess the amplification of the correct fragment. The expression of *FOXL2* mRNA was calculated and normalized to the reference gene *RPL19* using the relative standard curve method [98].

4.8. Western Blot Analysis

Total proteins were extracted from frozen tissue and Western blot immunoassays were processed with 15 µg of total protein extract, as described previously [52]. A rabbit anti-*FOXL2* purified antibody generated against a peptide corresponding to the C-terminal conserved region of mammalian *FOXL2* (WDHDSKTGALHSRLDL, diluted 1:500, CASLO Laboratory, Denmark) was used in PBS-T solution containing 4% non-fat dry milk and then, a goat peroxidase-conjugated anti-rabbit IgG antibody (diluted 1:5000, SantaCruz Biotechnology; Heidelberg, Germany). Actin B protein (ACTB) was assessed as a loading control, using a mouse monoclonal anti-ACTB antibody (diluted 1:2000, A1978—Sigma-Aldrich, Lyon, France) and goat peroxidase-conjugated anti-mouse IgG antibody (SantaCruz Biotechnology; Heidelberg, Germany; diluted 1:5 000). Immunoreaction signals were revealed with Luminata Classico HRP Substrates (Millipore, Guyancourt, France) and analysed using an image analysis system (Advanced Image Data Analyser Software, LAS 1000 camera; Fujifilm, FVST, Courbevoie, France).

4.9. Statistical Analyses

Statistical analyses were carried out using GraphPad Prism 6 software (GraphPad Software, USA). Quantitative data were explored using two-way-ANOVA followed by Bonferroni post hoc tests. Data were analysed for effects of day, pregnancy status (cyclic or pregnant), treatments (DMSO and Trilostane; E2, P4 and E2 + P4), endometrial areas (CAR and ICAR) and their interactions (day *versus* status or status *versus* endometrial areas). Quantitative data from the luciferase assays on COS7 cells were explored using one-way ANOVA followed by a nonparametric permutation test, the K-Sample Fisher–Pitman Permutation Test.

5. Conclusions

Using various and complementary experimental models carried out with ovine and bovine species as well as in vitro assays; our data have demonstrated FOXL2 as a progesterone-regulated gene in the endometrium of the ruminants. Additional investigation will be necessary to determine if this regulation applies to the endometrium of other mammalian species. Eventually identifying the molecular mechanisms that drive regulation of FOXL2 gene expression by progesterone in the uterus will provide novel insights about gene regulation by steroids in a tissue-specific manner.

Supplementary Materials: Supplementary materials can be found at <http://www.mdpi.com/1422-0067/21/4/1478/s1>.

Author Contributions: Conceptualization: C.E., S.C., D.V., A.M., I.M.S., F.C., M.P., O.S.; methodology, C.E., A.L.-P., V.M., G.D.H., P.B., C.G.-D., T.S.; data analysis and interpretation: C.E., G.D.H., S.C., D.V., A.M., I.M.S., F.C., M.P., O.S.; discussion of the findings: C.E., S.C., D.V., A.M., I.M.S., F.C., M.P., O.S.; funding acquisition: O.S.; writing—original draft preparation, C.E., O.S.; final editing: C.E., A.M., I.M.S., M.P., O.S.; project administration and supervision, C.E., O.S. All authors have read and agreed to the published version of the manuscript.

Funding: Financial support was provided by ANR-08-GENM-037 and AIP Bioressources CHIPSTRAFFIC. CE was a recipient of INRA-Phase Department and ANR-08-GENM-037.

Acknowledgments: We are very grateful to colleagues of the BDR laboratory (INRA, Jouy-en-Josas, France), namely E. Pailhous and A. Vitorino Carvalho for continuous support and helpful discussions, L. Gall for help in Western Blot procedure and P. Reinaud for advice in cell culture. We thank JP. Albert (Experimental unit of INRA, Jouy-en-Josas, France) and MC. Aubrière for animal management and tissue collection (INRA, Jouy-en-Josas, France), @BRIDGEplatform (Agilent Analyzer, INRA, Jouy-en-Josas).

Conflicts of Interest: The authors declare that there is no conflict of interest.

References

1. Bazer, F.W.; Wu, G.; Spencer, T.E.; Johnson, G.A.; Burghardt, R.C.; Bayless, K. Novel pathways for implantation and establishment and maintenance of pregnancy in mammals. *Mol. Hum. Reprod.* **2010**, *16*, 135–152. [CrossRef]
2. Lee, K.Y.; DeMayo, F.J. Animal models of implantation. *Reproduction* **2004**, *128*, 679–695. [CrossRef] [PubMed]
3. Sandra, O.; Charpigny, G.; Galio, L.; Hue, I. Preattachment Embryos of Domestic Animals: Insights into Development and Paracrine Secretions. *Annu. Rev. Anim. Biosci.* **2017**, *5*, 205–228. [CrossRef] [PubMed]
4. Spencer, T.E.; Hansen, T.R. Implantation and Establishment of Pregnancy in Ruminants. *Adv. Anat. Embryol. Cell Biol.* **2015**, *216*, 105–135. [PubMed]
5. Franczyk, M.; Lopucki, M.; Stachowicz, N.; Morawska, D.; Kankofer, M. Extracellular matrix proteins in healthy and retained placentas, comparing hemochorial and synepitheliochorial placentas. *Placenta* **2017**, *50*, 19–24. [CrossRef]
6. Hafez, S. Comparative Placental Anatomy: Divergent Structures Serving a Common Purpose. *Prog. Mol. Biol. Transl. Sci.* **2017**, *145*, 1–28. [PubMed]
7. Sandra, O.; Mansouri-Attia, N.; Lea, R.G. Novel aspects of endometrial function: A biological sensor of embryo quality and driver of pregnancy success. *Reprod. Fertil. Dev.* **2011**, *24*, 68–79. [CrossRef]
8. Amoako, A.A.; Nafee, T.M.; Ola, B. Epigenetic Influences During the Periconception Period and Assisted Reproduction. *Adv. Exp. Med. Biol.* **2017**, *1014*, 15–39.
9. Diskin, M.G.; Morris, D.G. Embryonic and early foetal losses in cattle and other ruminants. *Reprod. Domest. Anim.* **2008**, *43* (Suppl. 2), 260–267. [CrossRef]

10. Wiltbank, M.C.; Baez, G.M.; Garcia-Guerra, A.; Toledo, M.Z.; Monteiro, P.L.; Melo, L.F.; Ochoa, J.C.; Santos, J.E.; Sartori, R. Pivotal periods for pregnancy loss during the first trimester of gestation in lactating dairy cows. *Theriogenology* **2016**, *86*, 239–253. [[CrossRef](#)]
11. Al-Gubory, K.H.; Bolifraud, P.; Garrel, C. Regulation of Key Antioxidant Enzymatic Systems in the Sheep Endometrium by Ovarian Steroids. *Endocrinology* **2008**, *149*, 4428–4434. [[CrossRef](#)] [[PubMed](#)]
12. Devroey, P.; Pados, G. Preparation of endometrium for egg donation. *Hum. Reprod. Update* **1998**, *4*, 856–861. [[CrossRef](#)] [[PubMed](#)]
13. Miller, B.G.; Moore, N.W. Effects of progesterone and oestradiol on endometrial metabolism and embryo survival in the ovariectomized ewe. *Theriogenology* **1976**, *6*, 636. [[CrossRef](#)]
14. Ozturk, S.; Demir, R. Particular functions of estrogen and progesterone in establishment of uterine receptivity and embryo implantation. *Histol. Histopathol.* **2010**, *25*, 1215–1228.
15. Patel, B.; Elguero, S.; Thakore, S.; Dahoud, W.; Bedaiwy, M.; Mesiano, S. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. *Hum. Reprod. Update* **2015**, *21*, 155–173. [[CrossRef](#)]
16. Qu, T.; Zhang, S.M.; Yu, L.L.; Zhang, S.; Yuan, D.Z.; Xu, Q.; Zhang, J.H.; He, Y.P.; Yue, L.M. Relocalisation and activation of integrins induced rapidly by oestrogen via G-protein-coupled receptor 30 in mouse blastocysts. *Reprod. Fertil. Dev.* **2015**. [[CrossRef](#)]
17. Szekeres-Bartho, J.; Sucurovic, S.; Mulac-Jericevic, B. The Role of Extracellular Vesicles and PIBF in Embryo-Maternal Immune-Interactions. *Front. Immunol.* **2018**, *9*, 2890. [[CrossRef](#)]
18. Forde, N.; Beltman, M.E.; Lonergan, P.; Diskin, M.; Roche, J.F.; Crowe, M.A. Oestrous cycles in *Bos taurus* cattle. *Anim. Reprod. Sci.* **2011**, *124*, 163–169. [[CrossRef](#)]
19. Spencer, T.E.; Forde, N.; Lonergan, P. Insights into conceptus elongation and establishment of pregnancy in ruminants. *Reprod. Fertil. Dev.* **2016**, *29*, 84–100. [[CrossRef](#)]
20. De Ruijter-Villani, M.; Deelen, C.; Stout, T.A. Expression of leukaemia inhibitory factor at the conceptus/maternal interface during preimplantation development and in the endometrium during the oestrous cycle in the mare. *Reprod. Fertil. Dev.* **2015**. [[CrossRef](#)]
21. Hawkins, S.M.; Matzuk, M.M. The menstrual cycle: Basic biology. *Ann. N. Y. Acad. Sci.* **2008**, *1135*, 10–18. [[CrossRef](#)] [[PubMed](#)]
22. Mihm, M.; Gangooly, S.; Muttukrishna, S. The normal menstrual cycle in women. *Anim. Reprod. Sci.* **2011**, *124*, 229–236. [[CrossRef](#)] [[PubMed](#)]
23. Lonergan, P. Influence of progesterone on oocyte quality and embryo development in cows. *Theriogenology* **2011**, *76*, 1594–1601. [[CrossRef](#)] [[PubMed](#)]
24. Bazer, F.W.; Spencer, T.E.; Johnson, G.A.; Burghardt, R.C.; Wu, G. Comparative aspects of implantation. *Reproduction* **2009**, *138*, 195–209. [[CrossRef](#)]
25. Forde, N.; Lonergan, P. Transcriptomic analysis of the bovine endometrium: What is required to establish uterine receptivity to implantation in cattle? *J. Reprod. Dev.* **2012**, *58*, 189–195. [[CrossRef](#)]
26. Sanchez, J.M.; Randi, F.; Passaro, C.; Mathew, D.J.; Butler, S.T.; Lonergan, P. Effect of human chorionic gonadotrophin administration 2 days after insemination on progesterone concentration and pregnancy per artificial insemination in lactating dairy cows. *J. Dairy Sci.* **2018**, *101*, 6556–6567. [[CrossRef](#)]
27. Spencer, T.E.; Johnson, G.A.; Bazer, F.W.; Burghardt, R.C.; Palmarini, M. Pregnancy recognition and conceptus implantation in domestic ruminants: Roles of progesterone, interferons and endogenous retroviruses. *Reprod. Fertil. Dev.* **2007**, *19*, 65–78. [[CrossRef](#)]
28. Martal, J.; Lacroix, M.C.; Loudes, C.; Saunier, M.; Wintenberger-Torres, S. Trophoblastin, an antiluteolytic protein present in early pregnancy in sheep. *J. Reprod. Fertil.* **1979**, *56*, 63–73. [[CrossRef](#)]
29. Roberts, R.M.; Chen, Y.; Ezashi, T.; Walker, A.M. Interferons and the maternal-conceptus dialog in mammals. *Semin. Cell Dev. Biol.* **2008**, *19*, 170–177. [[CrossRef](#)]
30. Spencer, T.E.; Sandra, O.; Wolf, E. Genes involved in conceptus-endometrial interactions in ruminants: Insights from reductionism and thoughts on holistic approaches. *Reproduction* **2008**, *135*, 165–179. [[CrossRef](#)]
31. Hansen, T.R.; Sinedino, L.D.P.; Spencer, T.E. Paracrine and endocrine actions of interferon tau (IFNT). *Reproduction* **2017**, *154*, F45–F59. [[CrossRef](#)] [[PubMed](#)]
32. Imakawa, K.; Bai, R.; Kusama, K. Integration of molecules to construct the processes of conceptus implantation to the maternal endometrium. *J. Anim. Sci.* **2018**, *96*, 3009–3021. [[CrossRef](#)]
33. Lonergan, P.; Forde, N. The Role of Progesterone in Maternal Recognition of Pregnancy in Domestic Ruminants. *Adv. Anat. Embryol. Cell Biol.* **2015**, *216*, 87–104.

34. Wetendorf, M.; DeMayo, F.J. Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus. *Int. J. Dev. Biol.* **2014**, *58*, 95–106. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Marquardt, R.M.; Kim, T.H.; Shin, J.H.; Jeong, J.W. Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis? *Int. J. Mol. Sci.* **2019**, *20*, 3822. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Clemente, M.; de La Fuente, J.; Fair, T.; Al Naib, A.; Gutierrez-Adan, A.; Roche, J.F.; Rizos, D.; Lonergan, P. Progesterone and conceptus elongation in cattle: A direct effect on the embryo or an indirect effect via the endometrium? *Reproduction* **2009**, *138*, 507–517. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Okumu, L.A.; Forde, N.; Fahey, A.G.; Fitzpatrick, E.; Roche, J.F.; Crowe, M.A.; Lonergan, P. The effect of elevated progesterone and pregnancy status on mRNA expression and localisation of progesterone and oestrogen receptors in the bovine uterus. *Reproduction* **2010**, *140*, 143–153. [\[CrossRef\]](#)
38. Wang, X.; Wu, S.P.; DeMayo, F.J. Hormone dependent uterine epithelial-stromal communication for pregnancy support. *Placenta* **2017**, *60* (Suppl. 1), S20–S26. [\[CrossRef\]](#)
39. Wetendorf, M.; Wu, S.P.; Wang, X.; Creighton, C.J.; Wang, T.; Lanz, R.B.; Blok, L.; Tsai, S.Y.; Tsai, M.J.; Lydon, J.P.; et al. Decreased epithelial progesterone receptor A at the window of receptivity is required for preparation of the endometrium for embryo attachment. *Biol. Reprod.* **2017**, *96*, 313–326. [\[CrossRef\]](#)
40. Vasquez, Y.M.; Mazur, E.C.; Li, X.; Kommagani, R.; Jiang, L.; Chen, R.; Lanz, R.B.; Kovanci, E.; Gibbons, W.E.; DeMayo, F.J. FOXO1 is required for binding of PR on IRF4, novel transcriptional regulator of endometrial stromal decidualization. *Mol. Endocrinol.* **2015**, *29*, 421–433. [\[CrossRef\]](#)
41. Bauersachs, S.; Mitko, K.; Ulbrich, S.E.; Blum, H.; Wolf, E. Transcriptome studies of bovine endometrium reveal molecular profiles characteristic for specific stages of estrous cycle and early pregnancy. *Exp. Clin. Endocrinol. Diabetes* **2008**, *116*, 371–384. [\[CrossRef\]](#) [\[PubMed\]](#)
42. Bauersachs, S.; Wolf, E. Transcriptome analyses of bovine, porcine and equine endometrium during the pre-implantation phase. *Anim. Reprod. Sci.* **2012**, *134*, 84–94. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Biase, F.H.; Rabel, C.; Guillomot, M.; Hue, I.; Andropolis, K.; Olmstead, C.A.; Oliveira, R.; Wallace, R.; Le Bourhis, D.; Richard, C.; et al. Massive dysregulation of genes involved in cell signaling and placental development in cloned cattle conceptus and maternal endometrium. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 14492–14501. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Mansouri-Attia, N.; Aubert, J.; Reinaud, P.; Giraud-Delville, C.; Taghouti, G.; Galio, L.; Everts, R.E.; Degrelle, S.; Richard, C.; Hue, I.; et al. Gene expression profiles of bovine caruncular and intercaruncular endometrium at implantation. *Physiol. Genom.* **2009**, *39*, 14–27. [\[CrossRef\]](#)
45. McGettigan, P.A.; Browne, J.A.; Carrington, S.D.; Crowe, M.A.; Fair, T.; Forde, N.; Loftus, B.J.; Lohan, A.; Lonergan, P.; Pluta, K.; et al. Fertility and genomics: Comparison of gene expression in contrasting reproductive tissues of female cattle. *Reprod. Fertil. Dev.* **2016**, *28*, 11–24. [\[CrossRef\]](#)
46. Moraes, J.G.N.; Behura, S.K.; Geary, T.W.; Hansen, P.J.; Neiberghs, H.L.; Spencer, T.E. Uterine influences on conceptus development in fertility-classified animals. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E1749–E1758. [\[CrossRef\]](#)
47. Passaro, C.; Tutt, D.; Bages Arnal, S.; Maicas, C.; Laguna-Barraza, R.; Gutierrez-Adan, A.; Browne, J.A.; Rath, D.; Behura, S.K.; Spencer, T.; et al. Global transcriptomic response of bovine endometrium to blastocyst stage embryos. *Reproduction* **2019**. [\[CrossRef\]](#)
48. Satterfield, M.C.; Song, G.; Kochan, K.J.; Riggs, P.K.; Simmons, R.M.; Elsik, C.G.; Adelson, D.L.; Bazer, F.W.; Zhou, H.; Spencer, T.E. Discovery of candidate genes and pathways in the endometrium regulating ovine blastocyst growth and conceptus elongation. *Physiol. Genom.* **2009**, *39*, 85–99. [\[CrossRef\]](#)
49. Sponchiado, M.; Gomes, N.S.; Fontes, P.K.; Martins, T.; Del Collado, M.; Pastore, A.A.; Pugliesi, G.; Nogueira, M.F.G.; Binelli, M. Pre-hatching embryo-dependent and -independent programming of endometrial function in cattle. *PLoS ONE* **2017**, *12*, e0175954. [\[CrossRef\]](#)
50. Ulbrich, S.E.; Wolf, E.; Bauersachs, S. Hosting the preimplantation embryo: Potentials and limitations of different approaches for analysing embryo-endometrium interactions in cattle. *Reprod. Fertil. Dev.* **2012**, *25*, 62–70. [\[CrossRef\]](#)
51. Elzaia, M.; Todeschini, A.L.; Caburet, S.; Veitia, R.A. The genetic make-up of ovarian development and function: The focus on the transcription factor FOXL2. *Clin. Genet.* **2017**, *91*, 173–182. [\[CrossRef\]](#)

52. Eozenou, C.; Vitorino Carvalho, A.; Forde, N.; Giraud-Delville, C.; Gall, L.; Lonergan, P.; Auguste, A.; Charpigny, G.; Richard, C.; Pannetier, M.; et al. FOXL2 Is Regulated During the Bovine Estrous Cycle and Its Expression in the Endometrium Is Independent of Conceptus-Derived Interferon Tau. *Biol. Reprod.* **2012**. [[CrossRef](#)] [[PubMed](#)]
53. Georges, A.; Auguste, A.; Bessiere, L.; Vanet, A.; Todeschini, A.L.; Veitia, R.A. FOXL2: A central transcription factor of the ovary. *J. Mol. Endocrinol.* **2014**, *52*, R17–R33. [[CrossRef](#)] [[PubMed](#)]
54. Governini, L.; Carrarelli, P.; Rocha, A.L.; Leo, V.D.; Luddi, A.; Arcuri, F.; Piomboni, P.; Chapron, C.; Bilezikjian, L.M.; Petraglia, F. FOXL2 in human endometrium: Hyperexpressed in endometriosis. *Reprod. Sci.* **2014**, *21*, 1249–1255. [[CrossRef](#)]
55. Bellessort, B.; Bachelot, A.; Heude, E.; Alfama, G.; Fontaine, A.; Le Cardinal, M.; Treier, M.; Levi, G. Role of Foxl2 in uterine maturation and function. *Hum. Mol. Genet.* **2015**, *24*, 3092–3103. [[CrossRef](#)]
56. Elbaz, M.; Hadas, R.; Bilezikjian, L.M.; Gershon, E. Uterine Foxl2 regulates the adherence of the Trophectoderm cells to the endometrial epithelium. *Reprod. Biol. Endocrinol.* **2018**, *16*, 12. [[CrossRef](#)]
57. Al-Gubory, K.H.; Camous, S.; Germain, G.; Bolifraud, P.; Nicole, A.; Ceballos-Picot, I. Reconsideration of the proposed luteotropic and luteoprotective actions of ovine placental lactogen in sheep: In vivo and in vitro studies. *J. Endocrinol.* **2006**, *188*, 559–568. [[CrossRef](#)]
58. Shimizu, T.; Krebs, S.; Bauersachs, S.; Blum, H.; Wolf, E.; Miyamoto, A. Actions and interactions of progesterone and estrogen on transcriptome profiles of the bovine endometrium. *Physiol. Genom.* **2010**, *42A*, 290–300. [[CrossRef](#)]
59. Crisponi, L.; Deiana, M.; Loi, A.; Chiappe, F.; Uda, M.; Amati, P.; Bisceglia, L.; Zelante, L.; Nagaraja, R.; Porcu, S.; et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. *Nat. Genet.* **2001**, *27*, 159–166. [[CrossRef](#)]
60. Pannetier, M.; Pailhoux, E. Sex differentiation: State of the art and future prospects. *Med. Sci. (Paris)* **2011**, *27*, 859–865. [[CrossRef](#)]
61. Uhlenhaut, N.H.; Jakob, S.; Anlag, K.; Eisenberger, T.; Sekido, R.; Kress, J.; Treier, A.-C.; Klugmann, C.; Klasen, C.; Holter, N.I.; et al. Somatic Sex Reprogramming of Adult Ovaries to Testes by FOXL2 Ablation. *Cell* **2009**, *139*, 1130–1142. [[CrossRef](#)] [[PubMed](#)]
62. Uhlenhaut, N.H.; Treier, M. Forkhead transcription factors in ovarian function. *Reproduction* **2011**, *142*, 489–495. [[CrossRef](#)] [[PubMed](#)]
63. Abdoon, A.S.; Giraud-Delville, C.; Kandil, O.M.; Kerboeuf-Giraud, A.; Eozenou, C.; Carvalho, A.V.; Julian, S.; Sandra, O. Maternal recognition of pregnancy and implantation are not associated with an interferon response of the endometrium to the presence of the conceptus in dromedary camel. *Theriogenology* **2017**, *90*, 301–308. [[CrossRef](#)] [[PubMed](#)]
64. Bazer, F.W.; Johnson, G.A.; Wu, G. Amino acids and conceptus development during the peri-implantation period of pregnancy. *Adv. Exp. Med. Biol.* **2015**, *843*, 23–52.
65. Franco, H.L.; Jeong, J.W.; Tsai, S.Y.; Lydon, J.P.; DeMayo, F.J. In vivo analysis of progesterone receptor action in the uterus during embryo implantation. *Semin. Cell Dev. Biol.* **2008**, *19*, 178–186. [[CrossRef](#)]
66. Lydon, J.P.; DeMayo, F.J.; Funk, C.R.; Mani, S.K.; Hughes, A.R.; Montgomery, C.A., Jr.; Shyamala, G.; Conneely, O.M.; O'Malley, B.W. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. *Genes Dev.* **1995**, *9*, 2266–2278. [[CrossRef](#)]
67. Dinh, D.T.; Breen, J.; Akison, L.K.; DeMayo, F.J.; Brown, H.M.; Robker, R.L.; Russell, D.L. Tissue-specific progesterone receptor-chromatin binding and the regulation of progesterone-dependent gene expression. *Sci. Rep.* **2019**, *9*, 11966. [[CrossRef](#)]
68. Lieberman, B.A.; Bona, B.J.; Edwards, D.P.; Nordeen, S.K. The constitution of a progesterone response element. *Mol. Endocrinol.* **1993**, *7*, 515–527.
69. Yin, P.; Roqueiro, D.; Huang, L.; Owen, J.K.; Xie, A.; Navarro, A.; Monsivais, D.; Coon V, J.S.; Kim, J.J.; Dai, Y.; et al. Genome-wide progesterone receptor binding: Cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells. *PLoS ONE* **2012**, *7*, e29021. [[CrossRef](#)]
70. Pawar, S.; Hantak, A.M.; Bagchi, I.C.; Bagchi, M.K. Minireview: Steroid-regulated paracrine mechanisms controlling implantation. *Mol. Endocrinol.* **2014**, *28*, 1408–1422. [[CrossRef](#)]
71. Goddard, L.M.; Murphy, T.J.; Org, T.; Enciso, J.M.; Hashimoto-Partyka, M.K.; Warren, C.M.; Domigan, C.K.; McDonald, A.I.; He, H.; Sanchez, L.A.; et al. Progesterone receptor in the vascular endothelium triggers physiological uterine permeability preimplantation. *Cell* **2014**, *156*, 549–562. [[CrossRef](#)] [[PubMed](#)]

72. Popovici, R.M.; Betzler, N.K.; Krause, M.S.; Luo, M.; Jauckus, J.; Germeyer, A.; Bloethner, S.; Schlotterer, A.; Kumar, R.; Strowitzki, T.; et al. Gene Expression Profiling of Human Endometrial-Trophoblast Interaction in a Coculture Model. *Endocrinology* **2006**, *147*, 5662–5675. [[CrossRef](#)] [[PubMed](#)]
73. Talbi, S.; Hamilton, A.E.; Vo, K.C.; Tulac, S.; Overgaard, M.T.; Dosiou, C.; Le Shay, N.; Nezhat, C.N.; Kempson, R.; Lessey, B.A.; et al. Molecular Phenotyping of Human Endometrium Distinguishes Menstrual Cycle Phases and Underlying Biological Processes in Normo-Ovulatory Women. *Endocrinology* **2005**, *147*, 1097–1121. [[CrossRef](#)] [[PubMed](#)]
74. Nugent, B.M.; Tobet, S.A.; Lara, H.E.; Lucion, A.B.; Wilson, M.E.; Recabarren, S.E.; Paredes, A.H. Hormonal programming across the lifespan. *Horm. Metab. Res.* **2012**, *44*, 577–586. [[CrossRef](#)] [[PubMed](#)]
75. Pask, A.J.; Calatayud, N.E.; Shaw, G.; Wood, W.M.; Renfree, M.B. Oestrogen blocks the nuclear entry of SOX9 in the developing gonad of a marsupial mammal. *BMC Biol.* **2010**, *8*, 113. [[CrossRef](#)] [[PubMed](#)]
76. Pask, A.J. A role for estrogen in somatic cell fate of the mammalian gonad. *Chromosome Res.* **2012**, *20*, 239–245. [[CrossRef](#)]
77. Georges, A.; L'Hote, D.; Todeschini, A.L.; Auguste, A.; Legois, B.; Zider, A.; Veitia, R.A. The transcription factor FOXL2 mobilizes estrogen signaling to maintain the identity of ovarian granulosa cells. *Elife* **2014**. [[CrossRef](#)]
78. Pannetier, M.; Fabre, S.; Batista, F.; Kocer, A.; Renault, L.; Jolivet, G.; Mandon-Pepin, B.; Cotinot, C.; Veitia, R.; Pailhoux, E. FOXL2 activates P450 aromatase gene transcription: Towards a better characterization of the early steps of mammalian ovarian development. *J. Mol. Endocrinol.* **2006**, *36*, 399–413. [[CrossRef](#)]
79. Govoroun, M.S.; Pannetier, M.; Pailhoux, E.; Cocquet, J.; Brillard, J.P.; Couty, I.; Batellier, F.; Cotinot, C. Isolation of chicken homolog of the FOXL2 gene and comparison of its expression patterns with those of aromatase during ovarian development. *Dev. Dyn.* **2004**, *231*, 859–870. [[CrossRef](#)]
80. Baron, D. An evolutionary and functional analysis of FoxL2 in rainbow trout gonad differentiation. *J. Mol. Endocrinol.* **2004**, *33*, 705–715. [[CrossRef](#)]
81. Nakamoto, M.; Matsuda, M.; Wang, D.S.; Nagahama, Y.; Shibata, N. Molecular cloning and analysis of gonadal expression of Foxl2 in the medaka, *Oryzias latipes*. *Biochem. Biophys. Res. Commun.* **2006**, *344*, 353–361. [[CrossRef](#)] [[PubMed](#)]
82. Georges, A.; Benayoun, B.A.; Marongiu, M.; Dipietromaria, A.; L'Hote, D.; Todeschini, A.L.; Auer, J.; Crisponi, L.; Veitia, R.A. SUMOylation of the Forkhead transcription factor FOXL2 promotes its stabilization/activation through transient recruitment to PML bodies. *PLoS ONE* **2011**, *6*, e25463. [[CrossRef](#)] [[PubMed](#)]
83. Spencer, T.E.; Bazer, F.W. Biology of progesterone action during pregnancy recognition and maintenance of pregnancy. *Front. Biosci.* **2002**, *7*, d1879–d1898. [[CrossRef](#)] [[PubMed](#)]
84. Spencer, T.E.; Dunlap, K.A.; Filant, J. Comparative developmental biology of the uterus: Insights into mechanisms and developmental disruption. *Mol. Cell. Endocrinol.* **2012**, *354*, 34–53. [[CrossRef](#)] [[PubMed](#)]
85. Batista, F.; Vaiman, D.; Dausset, J.; Fellous, M.; Veitia, R.A. Potential targets of FOXL2, a transcription factor involved in craniofacial and follicular development, identified by transcriptomics. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 3330–3335. [[CrossRef](#)]
86. Moumné, L.; Batista, F.; Benayoun, B.A.; Nallathambi, J.; Fellous, M.; Sundaresan, P.; Veitia, R.A. The mutations and potential targets of the forkhead transcription factor FOXL2. *Mol. Cell. Endocrinol.* **2008**, *282*, 2–11. [[CrossRef](#)]
87. Geraldo, M.T.; Valente, G.T.; Braz, A.S.; Martins, C. The discovery of Foxl2 paralogs in chondrichthyan, coelacanth and tetrapod genomes reveals an ancient duplication in vertebrates. *Heredity (Edinb)* **2013**, *111*, 57–65. [[CrossRef](#)]
88. Wegman, P.; Gothlin Eremo, A.; Lindlof, A.; Karlsson, M.; Stal, O.; Wingren, S. Expression of the forkhead transcription factor FOXL2 correlates with good prognosis in breast cancer patients treated with tamoxifen. *Int. J. Oncol.* **2011**, *38*, 1145–1151. [[CrossRef](#)]
89. Sandra, O.; Bataillon, I.; Roux, P.; Martal, J.; Charpigny, G.; Reinaud, P.; Bolifraud, P.; Germain, G.; Al-Gubory, K.H. Suppressor of cytokine signalling (SOCS) genes are expressed in the endometrium and regulated by conceptus signals during early pregnancy in the ewe. *J. Mol. Endocrinol.* **2005**, *34*, 637–644. [[CrossRef](#)]

90. Degrelle, S.A.; Campion, E.; Cabau, C.; Piumi, F.; Reinaud, P.; Richard, C.; Renard, J.P.; Hue, I. Molecular evidence for a critical period in mural trophoblast development in bovine blastocysts. *Dev. Biol.* **2005**, *288*, 448–460. [[CrossRef](#)]
91. Solano, M.E.; Parker, V.J.; Camous, S.; Sandra, O.; Douglas, A.J.; Arck, P.C. Low doses of trilostane fail to induce abortion during early gestation in mice and ewes. *Am. J. Reprod. Immunol.* **2008**. [[CrossRef](#)]
92. Beard, A.P.; Hunter, M.G.; Lamming, G.E. Quantitative control of oxytocin-induced PGF2 alpha release by progesterone and oestradiol in ewes. *J. Reprod. Fertil.* **1994**, *100*, 143–150. [[CrossRef](#)] [[PubMed](#)]
93. Pant, H.C.; Hopkinson, C.R.; Fitzpatrick, R.J. Concentration of oestradiol, progesterone, luteinizing hormone and follicle-stimulating hormone in the jugular venous plasma of ewes during the oestrous cycle. *J. Endocrinol.* **1977**, *73*, 247–255. [[CrossRef](#)] [[PubMed](#)]
94. Borges, A.M.; Healey, G.D.; Sheldon, I.M. Explants of intact endometrium to model bovine innate immunity and inflammation ex vivo. *Am. J. Reprod. Immunol.* **2012**, *67*, 526–539. [[CrossRef](#)]
95. Saut, J.P.; Healey, G.D.; Borges, A.M.; Sheldon, I.M. Ovarian steroids do not affect bovine endometrial cytokine or chemokine responses to *Escherichia coli* or LPS in vitro. *Reproduction* **2014**, *148*, 593–606. [[CrossRef](#)]
96. Pannetier, M.; Renault, L.; Jolivet, G.; Cotinot, C.; Pailhoux, E. Ovarian-specific expression of a new gene regulated by the goat PIS region and transcribed by a FOXL2 bidirectional promoter. *Genomics* **2005**, *85*, 715–726. [[CrossRef](#)]
97. Kastner, P.; Bocquel, M.T.; Turcotte, B.; Garnier, J.M.; Horwitz, K.B.; Chambon, P.; Gronemeyer, H. Transient expression of human and chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms. *J. Biol. Chem.* **1990**, *265*, 12163–12167.
98. Larionov, A.; Krause, A.; Miller, W. A standard curve based method for relative real time PCR data processing. *BMC Bioinform.* **2005**, *6*, 62. [[CrossRef](#)] [[PubMed](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).